metformin has been researched along with lovastatin in 18 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 1 (5.56) | 18.7374 |
1990's | 1 (5.56) | 18.2507 |
2000's | 4 (22.22) | 29.6817 |
2010's | 10 (55.56) | 24.3611 |
2020's | 2 (11.11) | 2.80 |
Authors | Studies |
---|---|
Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
Lombardo, F; Obach, RS; Waters, NJ | 1 |
Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV | 1 |
Ekins, S; Williams, AJ; Xu, JJ | 1 |
Bellera, CL; Bruno-Blanch, LE; Castro, EA; Duchowicz, PR; Goodarzi, M; Ortiz, EV; Pesce, G; Talevi, A | 1 |
Artursson, P; Haglund, U; Karlgren, M; Kimoto, E; Lai, Y; Norinder, U; Vildhede, A; Wisniewski, JR | 1 |
Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
Agard, DA; Ashworth, A; Barrio-Hernandez, I; Batra, J; Beltrao, P; Bennett, MJ; Bohn, M; Bouhaddou, M; Braberg, H; Broadhurst, DJ; Cai, Y; Cakir, M; Calviello, L; Cavero, DA; Chang, JCJ; Chorba, JS; Craik, CS; d'Enfert, C; Dai, SA; Eckhardt, M; Emerman, M; Fabius, JM; Fletcher, SJ; Floor, SN; Foussard, H; Frankel, AD; Fraser, JS; Fujimori, DG; Ganesan, SJ; García-Sastre, A; Gordon, DE; Gross, JD; Guo, JZ; Haas, K; Haas, P; Hernandez-Armenta, C; Hiatt, J; Huang, XP; Hubert, M; Hüttenhain, R; Ideker, T; Jacobson, M; Jang, GM; Jura, N; Kaake, RM; Kim, M; Kirby, IT; Klippsten, S; Koh, C; Kortemme, T; Krogan, NJ; Kuzuoglu-Ozturk, D; Li, Q; Liboy-Lugo, J; Lin, Y; Liu, X; Liu, Y; Lou, K; Lyu, J; Mac Kain, A; Malik, HS; Mathy, CJP; McGregor, MJ; Melnyk, JE; Memon, D; Meyer, B; Miorin, L; Modak, M; Moreno, E; Mukherjee, S; Naing, ZZC; Noack, J; O'Meara, MJ; O'Neal, MC; Obernier, K; Ott, M; Peng, S; Perica, T; Pilla, KB; Polacco, BJ; Rakesh, R; Rathore, U; Rezelj, VV; Richards, AL; Roesch, F; Rosenberg, OS; Rosenthal, SB; Roth, BL; Roth, TL; Ruggero, D; Safari, M; Sali, A; Saltzberg, DJ; Savar, NS; Schwartz, O; Sharp, PP; Shen, W; Shengjuler, D; Shi, Y; Shoichet, BK; Shokat, KM; Soucheray, M; Stroud, RM; Subramanian, A; Swaney, DL; Taunton, J; Tran, QD; Trenker, R; Tummino, TA; Tutuncuoglu, B; Ugur, FS; Vallet, T; Venkataramanan, S; Verba, KA; Verdin, E; Vignuzzi, M; von Zastrow, M; Wang, HY; Wankowicz, SA; Wenzell, NA; White, KM; Xu, J; Young, JM; Zhang, Z; Zhou, Y | 1 |
Paoletti, R; Sirtori, CR; Tremoli, E | 1 |
Bjerve, KS; Carlsen, SM; Følling, I; Rossvoll, O | 1 |
Dolovcak, S; Emmett, D; Esser, V; Fitz, JG; Kilic, G; Parameswara, V; Puljak, L; Waldrop, SL | 1 |
Fritz, G; Huelsenbeck, J; Nilsson, S | 1 |
Dayekh, K; Dimitroulakos, J; Gorn-Hondermann, I; Ma, L; Niknejad, N | 1 |
Lau-Cam, CA; Pandya, K | 1 |
Alonso, DF; Farina, HG | 1 |
2 review(s) available for metformin and lovastatin
Article | Year |
---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
New strategies in the development of anti-atherosclerotic drugs.
Topics: 4-Aminobenzoic Acid; Animals; Arteriosclerosis; Aspirin; Coronary Disease; Fatty Acids, Nonesterified; Hepatomegaly; Humans; Hydrogen Peroxide; Hypolipoproteinemias; Lovastatin; Male; Metformin; Microbodies; Naphthalenes; Oligopeptides; para-Aminobenzoates; Platelet Aggregation; Rats | 1980 |
1 trial(s) available for metformin and lovastatin
Article | Year |
---|---|
Metformin improves blood lipid pattern in nondiabetic patients with coronary heart disease.
Topics: Blood Glucose; Body Weight; Combined Modality Therapy; Coronary Disease; Diet; Humans; Hyperlipidemias; Hypolipidemic Agents; Life Style; Lipids; Lovastatin; Male; Metformin; Middle Aged; Prospective Studies | 1996 |
15 other study(ies) available for metformin and lovastatin
Article | Year |
---|---|
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations | 2010 |
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands | 2010 |
Prediction of drug intestinal absorption by new linear and non-linear QSPR.
Topics: Humans; Intestinal Absorption; Linear Models; Molecular Conformation; Nonlinear Dynamics; Permeability; Pharmaceutical Preparations; Probability; Quantitative Structure-Activity Relationship; Thermodynamics | 2011 |
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
Topics: Atorvastatin; Biological Transport; Drug Interactions; Estradiol; Estrone; HEK293 Cells; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Least-Squares Analysis; Liver; Liver-Specific Organic Anion Transporter 1; Models, Molecular; Multivariate Analysis; Organic Anion Transporters; Organic Anion Transporters, Sodium-Independent; Protein Isoforms; Pyrroles; Solute Carrier Organic Anion Transporter Family Member 1B3; Structure-Activity Relationship; Transfection | 2012 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
A SARS-CoV-2 protein interaction map reveals targets for drug repurposing.
Topics: Animals; Antiviral Agents; Betacoronavirus; Chlorocebus aethiops; Cloning, Molecular; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Drug Evaluation, Preclinical; Drug Repositioning; HEK293 Cells; Host-Pathogen Interactions; Humans; Immunity, Innate; Mass Spectrometry; Molecular Targeted Therapy; Pandemics; Pneumonia, Viral; Protein Binding; Protein Biosynthesis; Protein Domains; Protein Interaction Mapping; Protein Interaction Maps; Receptors, sigma; SARS-CoV-2; SKP Cullin F-Box Protein Ligases; Vero Cells; Viral Proteins | 2020 |
Evidence for AMPK-dependent regulation of exocytosis of lipoproteins in a model liver cell line.
Topics: Aminoimidazole Carboxamide; Amiodarone; AMP-Activated Protein Kinases; Animals; Apolipoproteins B; Cell Line; Enzyme Inhibitors; Epoxy Compounds; Exocytosis; Fatty Acids; Hepatocytes; Humans; Hypoglycemic Agents; Lipid Metabolism; Lovastatin; Metformin; Multienzyme Complexes; Oxidation-Reduction; Patch-Clamp Techniques; Protein Serine-Threonine Kinases; Rats; Ribonucleotides; Sterol Regulatory Element Binding Protein 1; Triglycerides | 2008 |
Mevalonate pathway inhibitors affect anticancer drug-induced cell death and DNA damage response of human sarcoma cells.
Topics: Antineoplastic Agents; Apoptosis; Blotting, Western; Bone Neoplasms; Cell Cycle; Cell Proliferation; Cisplatin; Diphosphonates; DNA Damage; Doxorubicin; Fibrosarcoma; Humans; Lovastatin; Metformin; Mevalonic Acid; Osteosarcoma; Phosphorylation; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Signal Transduction; Tumor Cells, Cultured; Tumor Suppressor Protein p53 | 2011 |
Lovastatin induces multiple stress pathways including LKB1/AMPK activation that regulate its cytotoxic effects in squamous cell carcinoma cells.
Topics: AMP-Activated Protein Kinase Kinases; AMP-Activated Protein Kinases; Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Squamous Cell; Cell Line; Cell Line, Tumor; Drug Synergism; Fibroblasts; Gefitinib; Gene Deletion; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemic Agents; Lovastatin; Metformin; Mice; Protein Serine-Threonine Kinases; Quinazolines; Signal Transduction | 2012 |
Taurine Improves the Actions of Metformin and Lovastatin on Plasma Markers of Carbohydrate and Lipid Dysfunction of Diabetic Rats.
Topics: Animals; Blood Glucose; Carbohydrates; Diabetes Mellitus, Experimental; Hypoglycemic Agents; Hypolipidemic Agents; Insulin; Lipids; Lovastatin; Male; Metformin; Rats; Rats, Sprague-Dawley; Streptozocin; Taurine | 2019 |
Repurposing of host-based therapeutic agents for the treatment of coronavirus disease 2019 (COVID-19): a link between antiviral and anticancer mechanisms?
Topics: Anticholesteremic Agents; Antineoplastic Agents; Antiparasitic Agents; Antiviral Agents; Betacoronavirus; Coronavirus Infections; COVID-19; Drug Administration Schedule; Drug Repositioning; Host-Pathogen Interactions; Humans; Hypoglycemic Agents; Ivermectin; Lovastatin; Metformin; Nitro Compounds; Pandemics; Pneumonia, Viral; SARS-CoV-2; Severity of Illness Index; Thiazoles | 2020 |